共 50 条
- [41] Combined therapy with methotrexate nanoconjugate and dendritic cells with downregulated IL-10R expression modulates the tumor microenvironment and enhances the systemic anti-tumor immune response in MC38 murine colon carcinomaFRONTIERS IN IMMUNOLOGY, 2023, 14Szczygiel, AgnieszkaWegierek-Ciura, KatarzynaWroblewska, AnnaMierzejewska, JagodaRossowska, JoannaSzermer-Olearnik, BozenaSwitalska, MartaAnger-Gora, NataliaGoszczynski, Tomasz M.Pajtasz-Piasecka, Elzbieta
- [42] Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti-PD-1 TherapyJOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (07) : 1490 - 1496Inozume, TakashiYaguchi, TomonoriAriyasu, RyoTogashi, YosukeOhnuma, TakehiroHonobe, AkikoNishikawa, HiroyoshiKawakami, YutakaKawamura, Tatsuyoshi
- [43] Systemic depletion of CD4+CD25+T regulatory cells (Tregs) enhances the therapeutic anti-tumor effects of a recombinant vaccinia virus vaccine encoding tumor-specific MHC Class I and Class II dominant epitopes and the GM-CSF geneCANCER RESEARCH, 2006, 66 (08)Gabriel, Emmanuel M.Monken, Claude E.Lattime, Edmund C.
- [44] MHC Class I and PD-L1 Expression May Predict Treatment Response to Anti-PD-1/PD-L1 Therapy in Breast Cancer PatientsMODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 160 - 161Maniaci, JosephMills, AnneDillon, PatrickGaughan, ElizabethJenkins, Taylor
- [45] MHC Class I and PD-L1 Expression May Predict Treatment Response to Anti-PD-1/PD-L1 Therapy in Breast Cancer PatientsLABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 160 - 161Maniaci, JosephMills, AnneDillon, PatrickGaughan, ElizabethJenkins, Taylor
- [46] SIGNIFICANT ANTI-TUMOR ACTIVITY OF HBI-8000, A CLASS I HISTONE DEACETYLASE INHIBITOR (HDACI) IN COMBINATION WITH NIVOLUMAB (NIVO) IN ANTI-PD1 THERAPY-NAIVE ADVANCED MELANOMA (TN-MEL)JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A476 - A477Khushalani, NikhilBrohl, AndrewMarkowitz, JosephBazhenova, LyudmilaDaniels, GregoryYeckes-Rodin, HeatherFu, SiqingMcCormick, LoriKurman, MichaelGillings, MireilleLee, GloriaEroglu, Zeynep
- [47] Anti-tumor vaccination in advanced malignancy with class I and II htert peptide pulsed dendritic cells (dcs) fails to enhance antigen specific cd8+cytotoxic t cell (ctl) responses and generates regulatory t cells in circulationCANCER RESEARCH, 2008, 68 (09)Aloysius, MarkVerma, ChandanRobins, RichardEremin, JenniferSrinivasan, ThiagarajanFarzaneh, FarzinHardwick, NicolaHabib, NagyMc Kechnie, AlastairHarrison, PhillipEl-Sheemy, MohamadEremin, Oleg
- [48] RTX-321, an allogeneic artificial antigen presenting red cell therapeutic, expressing MHC I-Peptide, 41BBL and IL12, promotes antigen-specific T cell expansion and anti-tumor activity in HPV16+tumorsJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7Zhang, XuqingChen, Tiffany
- [49] PEPTIDE-ANTIBODY CONJUGATES FOR TUMOR-THERAPY - A MHC-CLASS-II-RESTRICTED TETANUS TOXIN PEPTIDE COUPLED TO AN ANTI-IG LIGHT-CHAIN ANTIBODY CAN INDUCE CYTOTOXIC LYSIS OF A HUMAN B-CELL LYMPHOMA BY SPECIFIC CD4 T-CELLSINTERNATIONAL JOURNAL OF CANCER, 1994, 56 (02) : 244 - 248YU, ZWHEALY, FVALMORI, DESCOBAR, PCORRADIN, GMACH, JP
- [50] MHC Class I-Restricted Human Melanoma Epitope Specific TCR Engineered Human CD4 T Cells Exhibit Anti-Tumor Effector Function, Proliferate upon Cognate Stimulation, Amplify CD8+CTL Generation, and Mitigate Inducible T Regulatory Cell (iTreg) Activities in Human Melanoma, in vitroCLINICAL IMMUNOLOGY, 2009, 131 : S39 - S39Chhabra, ArvindRay, SwagatamChakraborty, NityaRibas, AntoniEconomou, JamesMukherji, Bijay